Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
Open Access
- 27 March 2024
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (9) , 1096-1110
Abstract
Summary: Background/Aims: We examined the effects of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) initiation on long‐term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using real‐world data from the MarketScan database.Methods: We conducted a retrospective cohort study of patients with MASLD cirrhosis and type 2 diabetes between 2012 and 2020. Cox proportional hazard models examine the association between GLP‐1RAs initiation, modelled as time‐dependent, and the risk of ALO, a composite endpoint defined by the first occurrence of hepatic decompensation(s), portal hypertension, hepatocellular carcinoma (HCC) or liver transplantation (LT). We used Overlap Propensity Score Weighting (OPSW) to account for confounding. The study included 459 GLP‐1RAs and 4837 non‐GLP‐1RAs patients.Results: The non‐GLP‐1RAs patients presented with 1411 (29%) ALO over 7431.7 person years, while GLP‐1RAs patients had 32 (7%) ALO over 586.6 person years – risk rate difference 13.5 (95% CI: 11.4–15.7) per 100 person‐years. The OPSW‐adjusted risk of ALO was reduced by 36% (hazard ratio [HR]: 0.64; 95% CI: 0.54–0.76) in patients with vs. without GLP‐1RAs initiation. GLP‐1RAs initiation was associated with significant reductions in the adjusted risk of hepatic decompensation (HR: 0.74; 95% CI: 0.61–0.88), portal hypertension (HR: 0.73; 95% CI: 0.60–0.88), HCC (HR: 0.37; 95% CI: 0.20–0.63) and LT (HR: 0.24; 95% CI: 0.12–0.43).Conclusion: The use of GLP‐1RAs was associated with significant risk reductions in long‐term adverse liver outcomes, including hepatic decompensation, portal hypertension, HCC and LT, in MASLD cirrhosis patients with type 2 diabetes.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR002733)
- National Cancer Institute (P30CA016058)
This publication has 44 references indexed in Scilit:
- Identifying inpatient mortality in MarketScan claims data using machine learningPharmacoepidemiology and Drug Safety, 2023
- Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver DiseaseJAMA Network Open, 2022
- Overlap WeightingJAMA, 2020
- Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases—meta‐analytic assessmentCancer Medicine, 2019
- The high burden of alcoholic cirrhosis in privately insured persons in the United StatesHepatology, 2018
- Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community studyHepatology, 2017
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- Validation of three coding algorithms to identify patients with end‐stage liver disease in an administrative databasePharmacoepidemiology and Drug Safety, 2012
- Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studiesInternational Journal of Cancer, 2011
- A non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder biasStatistics in Medicine, 1984